Pharmacokinetics and Safety of Deuremidevir Hydrobromide (JT001) in Subjects with Mild and Moderate Renal Impairment: An Open‐Label, Parallel‐Group Phase I Study
Oct 2026· Journal of clinical pharmacology· Vol 66· 0 citations· 20 references
Medicine
TL;DR
Simulations suggested that the approved regimen was suitable for patients with mild renal impairment, whereas a reduced regimen of 300 mg twice daily on Day 1 followed by 200 mg twice daily on Days 2–5 was recommended for patients with moderate renal impairment.
Abstract
JT001 (deuremidevir hydrobromide, VV116) is an oral antiviral prodrug that is rapidly converted in vivo to its active metabolite, 116‐N1. Since 116‐N1 is mainly cleared by the kidneys, renal impairment may increase its systemic exposure. This study evaluated the pharmacokinetics of 116‐N1 following a single 0.3‐g oral dose of JT001 in participants with mild or moderate renal impairment and matched healthy controls. Absorption was generally similar across groups, with comparable time to peak concentration. However, declining renal function increased exposure to 116‐N1 and slowed its elimination. Terminal half‐life increased from 5.31 to 8.13 and 11.2 h in mild and moderate impairment. Apparent oral clearance decreased from 34.3 L/h in healthy participants to 21.4 and 13.8 L/h in patients with mild and moderate renal impairment, respectively. Twenty‐four participants (eight per renal function group) were enrolled. Geometric mean AUC0–t increased by 63% in participants with mild renal impairment (geometric mean ratio [GMR] 163.31%, 90% CI 135.99%–196.12%) and by 157% in those with moderate renal impairment (GMR 257.42%, 90% CI 214.35%–309.13%), whereas Cmax remained comparable between groups. JT001 was generally well tolerated, with no serious or grade ≥3 treatment‐related adverse events. To further assess clinical relevance of these findings, the renal impairment data were incorporated into an updated population pharmacokinetic model. Simulations suggested that the approved regimen was suitable for patients with mild renal impairment, whereas a reduced regimen of 300 mg twice daily on Day 1 followed by 200 mg twice daily on Days 2–5 was recommended for patients with moderate renal impairment.
Oral EGT710 (capsule and suspension) was safe and well tolerated, with pharmacokinetics that support further development as a treatment for coronavirus disease.
J. Oosterhaven, Jonathan Trolander, Lidiya Bebrevska et al.· Clinical pharmacology in dru...· 1 citation
ABSTRACT Ledaborbactam etzadroxil is an orally bioavailable prodrug of ledaborbactam, a broad-spectrum β-lactamase inhibitor being developed in combination with ceftibuten for the treatment of complicated urinary tract infections caused by antibiotic-resistant pathogens. As both agents are primarily eliminated via rena...
C. F. de Oliveira, Kathryn Lowe, Penny Fatato et al.· Antimicrobial Agents and Che...· 0 citations
ABSTRACT Zastaprazan (JP‐1366) is a novel potassium‐competitive acid blocker characterized by rapid onset and sustained acid suppression. This study aimed to evaluate the effect of food on the pharmacokinetics (PK), pharmacodynamics (PD), and safety of zastaprazan in healthy participants. In this randomized, open‐label...
Hyoeun Lee, Seok-Kyu Yoon, Soo-Min Jung et al.· Clinical and Translational S...· 0 citations
INTRODUCTION
Fluconazole is a triazole antifungal agent commonly used to treat both systemic and superficial fungal infections. This comprehensive review aims to collate all published pharmacokinetic (PK) data on fluconazole in healthy and diseased subjects.
METHODS
A systematic search of Google Scholar, PubMed, and...
Tahira Saleem, Khadija Ameen, M. Rasool et al.· Expert Review of Anti-Infect...· 0 citations
ICP-332 is a novel, orally administered TYK2 inhibitor with high selectivity, intended for the treatment of immune inflammatory diseases such as atopic dermatitis, psoriatic arthritis, inflammatory bowel disease and lupus. This Phase I study assessed its safety, pharmacokinetics, pharmacodynamics, and food effect i...
Heng-Li Zhao, Yi-Lin Wei, Yu Jiang et al.· Frontiers in Pharmacology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.